1
|
Gilyazova I, Asadullina D, Kagirova E, Sikka R, Mustafin A, Ivanova E, Bakhtiyarova K, Gilyazova G, Gupta S, Khusnutdinova E, Gupta H, Pavlov V. MiRNA-146a-A Key Player in Immunity and Diseases. Int J Mol Sci 2023; 24:12767. [PMID: 37628949 PMCID: PMC10454149 DOI: 10.3390/ijms241612767] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 08/09/2023] [Accepted: 08/10/2023] [Indexed: 08/27/2023] Open
Abstract
miRNA-146a, a single-stranded, non-coding RNA molecule, has emerged as a valuable diagnostic and prognostic biomarker for numerous pathological conditions. Its primary function lies in regulating inflammatory processes, haemopoiesis, allergic responses, and other key aspects of the innate immune system. Several studies have indicated that polymorphisms in miRNA-146a can influence the pathogenesis of various human diseases, including autoimmune disorders and cancer. One of the key mechanisms by which miRNA-146a exerts its effects is by controlling the expression of certain proteins involved in critical pathways. It can modulate the activity of interleukin-1 receptor-associated kinase, IRAK1, IRAK2 adaptor proteins, and tumour necrosis factor (TNF) targeting protein receptor 6, which is a regulator of the TNF signalling pathway. In addition, miRNA-146a affects gene expression through multiple signalling pathways, such as TNF, NF-κB and MEK-1/2, and JNK-1/2. Studies have been carried out to determine the effect of miRNA-146a on cancer pathogenesis, revealing its involvement in the synthesis of stem cells, which contributes to tumourigenesis. In this review, we focus on recent discoveries that highlight the significant role played by miRNA-146a in regulating various defence mechanisms and oncogenesis. The aim of this review article is to systematically examine miRNA-146a's impact on the control of signalling pathways involved in oncopathology, immune system development, and the corresponding response to therapy.
Collapse
Affiliation(s)
- Irina Gilyazova
- Subdivision of the Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, 450054 Ufa, Russia (E.K.)
| | - Dilara Asadullina
- Institute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia (A.M.); (G.G.)
| | - Evelina Kagirova
- Institute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia (A.M.); (G.G.)
| | - Ruhi Sikka
- Department of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Mathura 281406, India
| | - Artur Mustafin
- Institute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia (A.M.); (G.G.)
| | - Elizaveta Ivanova
- Subdivision of the Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, 450054 Ufa, Russia (E.K.)
| | - Ksenia Bakhtiyarova
- Institute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia (A.M.); (G.G.)
| | - Gulshat Gilyazova
- Institute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia (A.M.); (G.G.)
| | - Saurabh Gupta
- Department of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Mathura 281406, India
| | - Elza Khusnutdinova
- Subdivision of the Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, 450054 Ufa, Russia (E.K.)
- Institute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia (A.M.); (G.G.)
| | - Himanshu Gupta
- Department of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Mathura 281406, India
| | - Valentin Pavlov
- Institute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia (A.M.); (G.G.)
| |
Collapse
|
2
|
Bando K, Tanaka Y, Winias S, Sugawara S, Mizoguchi I, Endo Y. IL-33 induces histidine decarboxylase, especially in c-kit + cells and mast cells, and roles of histamine include negative regulation of IL-33-induced eosinophilia. Inflamm Res 2023; 72:651-667. [PMID: 36723628 DOI: 10.1007/s00011-023-01699-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 01/12/2023] [Accepted: 01/23/2023] [Indexed: 02/02/2023] Open
Abstract
OBJECTIVE AND METHODS IL-33 is present in endothelial, epithelial, and fibroblast-like cells and released upon cell injury. IL-33 reportedly induces mast-cell degranulation and is involved in various diseases, including allergic diseases. So, IL-33-related diseases seem to overlap with histamine-related diseases. In addition to the release from mast cells, histamine is newly formed by the induction of histidine decarboxylase (HDC). Some inflammatory and/or hematopoietic cytokines (IL-1, IL-3, etc.) are known to induce HDC, and the histamine produced by HDC induction is released without storage. We examined the involvement of HDC and histamine in the effects of IL-33. RESULTS A single intraperitoneal injection of IL-33 into mice induced HDC directly and/or via other cytokines (including IL-5) within a few hours in various tissues, particularly strongly in hematopoietic organs. The major cells exhibiting HDC-induction were mast cells and c-kit+ cells in the bone marrow. HDC was also induced in non-mast cells in non-hematopoietic organs. HDC, histamine, and histamine H4 receptors (H4Rs) contributed to the suppression of IL-33-induced eosinophilia. CONCLUSION IL-33 directly and indirectly (via IL-5) induces HDC in various cells, particularly potently in c-kit+ cells and mature mast cells, and the newly formed histamine contributes to the negative regulation of IL-33-induced eosinophilia via H4Rs.
Collapse
Affiliation(s)
- Kanan Bando
- Division of Orthodontics and Dentofacial Orthopedics, Graduate School of Dentistry, Tohoku University, 4-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8575, Japan.
| | - Yukinori Tanaka
- Division of Dento-Oral Anesthesiology, Graduate School of Dentistry, Tohoku University, 4-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8575, Japan
| | - Saka Winias
- Division of Dento-Oral Anesthesiology, Graduate School of Dentistry, Tohoku University, 4-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8575, Japan
| | - Shunji Sugawara
- Division of Oral Immunology, Tohoku University Graduate School of Dentistry, 4-1 Seiryo-Machi, Sendai, 980-8575, Japan
| | - Itaru Mizoguchi
- Division of Orthodontics and Dentofacial Orthopedics, Graduate School of Dentistry, Tohoku University, 4-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8575, Japan
| | - Yasuo Endo
- Division of Oral and Maxillofacial Surgery, Tohoku University Graduate School of Dentistry, 4-1 Seiryo-Machi, Sendai, 980-8575, Japan
| |
Collapse
|
3
|
Abiuso AMB, Varela ML, Haro Durand L, Besio Moreno M, Marcos A, Ponzio R, Rivarola MA, Belgorosky A, Pignataro OP, Berensztein E, Mondillo C. Histamine H4 receptor as a novel therapeutic target for the treatment of Leydig-cell tumours in prepubertal boys. Eur J Cancer 2018; 91:125-135. [PMID: 29367056 DOI: 10.1016/j.ejca.2017.12.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Revised: 10/18/2017] [Accepted: 12/07/2017] [Indexed: 12/16/2022]
Abstract
Leydig-cell tumours (LCTs) are rare endocrine tumours of the testicular interstitium, with recent increased incidence. Symptoms include precocious puberty in children; and erectile dysfunction, infertility and/or gynaecomastia, in adults. So far, scientific evidence points to aromatase (CYP19) overexpression and excessive oestrogen and insulin-like growth factor (IGF) -1 production as responsible for Leydig-cell tumourigenesis. LCTs are usually benign; however, malignant LCTs respond poorly to chemo/radiotherapy, highlighting the need to identify novel targets for treatment. Herein, we investigated the potential role of the histamine receptor H4 (HRH4) as a therapeutic target for LCTs using R2C rat Leydig tumour cells, a well-documented in vitro model for Leydigioma. Also, we studied for the first time the expression of CYP19, IGF-1R, oestrogen receptor (ER) α, ERβ, androgen receptor (AR) and HRH4 in human prepubertal LCTs versus normal prepubertal testes (NPTs). HRH4 agonist treatment inhibited steroidogenesis and proliferation in R2C cells and also negatively affected their pro-angiogenic capacity in vitro and in vivo, as assessed by evaluating the proliferative activity of human umbilical vein endothelial cells and by means of the quail chorioallantoic membrane assay, respectively. Moreover, E2 and IGF-1 inhibited HRH4 mRNA and protein levels. In human prepubertal LCTs, CYP19, IGF-1R, ERα and ERβ were overexpressed compared with NPTs. In contrast, HRH4 staining was weak in LCTs, but moderate/strong and confined to the interstitium in NPTs. Importantly, HRH4 was absent or barely detectable in seminiferous tubules or germ cells. Overall, our results point to HRH4 as a novel therapeutic target in LCTs.
Collapse
Affiliation(s)
- Adriana María Belén Abiuso
- Laboratorio de Endocrinología Molecular y Transducción de Señales, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Vuelta de Obligado 2490, C1428ADN, Buenos Aires, Argentina
| | - María Luisa Varela
- Laboratorio de Endocrinología Molecular y Transducción de Señales, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Vuelta de Obligado 2490, C1428ADN, Buenos Aires, Argentina
| | - Luis Haro Durand
- Laboratorio de Patología y Farmacología Molecular, IBYME-CONICET, Buenos Aires, Argentina
| | - Marcos Besio Moreno
- Laboratorio de Endocrinología Molecular y Transducción de Señales, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Vuelta de Obligado 2490, C1428ADN, Buenos Aires, Argentina
| | - Alejandra Marcos
- Laboratorio de Endocrinología Molecular y Transducción de Señales, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Vuelta de Obligado 2490, C1428ADN, Buenos Aires, Argentina
| | - Roberto Ponzio
- Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Marco Aurelio Rivarola
- Servicio de Endocrinología, Hospital de Pediatría "Prof. Dr.Juan P. Garrahan", Buenos Aires, Argentina
| | - Alicia Belgorosky
- Servicio de Endocrinología, Hospital de Pediatría "Prof. Dr.Juan P. Garrahan", Buenos Aires, Argentina
| | - Omar Pedro Pignataro
- Laboratorio de Endocrinología Molecular y Transducción de Señales, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Vuelta de Obligado 2490, C1428ADN, Buenos Aires, Argentina; Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Esperanza Berensztein
- Servicio de Endocrinología, Hospital de Pediatría "Prof. Dr.Juan P. Garrahan", Buenos Aires, Argentina
| | - Carolina Mondillo
- Laboratorio de Endocrinología Molecular y Transducción de Señales, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Vuelta de Obligado 2490, C1428ADN, Buenos Aires, Argentina.
| |
Collapse
|
4
|
Chen HX, Liu YS, Zhang XJ. TargetScore used to reveal potential targets of miRNA203 and miRNA-146a in psoriasis by integrating microRNA overexpression and microarray data. Medicine (Baltimore) 2018; 97:e12671. [PMID: 30313058 PMCID: PMC6203501 DOI: 10.1097/md.0000000000012671] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
OBJECTIVE Systematic tracking of microRNA (miRNA) targets remains a challenge. In our work, we aimed to use TargetScore to investigate the potential targets of miRNA203 and miRNA-146a in psoriasis by integrating miRNA overexpression information and sequence data, and to further uncover the functions of miRNA203 and miRNA-146a in psoriasis. METHODS This was a case-control bioinformatics analysis using already published microarray data of psoriasis. We calculated targetScores by combining log fold-change and sequence scores obtained from TargetScan context score, probabilities of conserved targeting, and derived the distribution of targetScores. The scoring cutoff was chosen based on the different targetScore distributions for the nonvalidated and validated targets. The potential target genes for miRNA-203 and miRNA-146a were predicted based on the targetScore threshold. To reveal the functions of miRNA-203 and miRNA-146a, we implemented pathway enrichment analyses for the targets of miRNA-203 and miRNA-146a. RESULTS TargetScore >0.4 was selected as the threshold to filter out less confidence targets because we observed little overlap between the 2 distribution at targetScore = 0.4. Based on the targetScore >0.4, 49 target genes for miRNA-203 and 17 targets for miRNA-146a were identified. Pathway enrichment results showed that the target genes of miRNA-203 (including KIR2DL1, HLA-DQA1, KIR3DL1) only participated in antigen processing and presentation. The target genes of miRNA-146a (covering ADORA3, CYSLTR2, HRH4) were only involved in neuroactive ligand-receptor interaction. CONCLUSION MiRNA203 and miRNA-146a played important roles in psoriasis progression, partially through regulating the pathways of antigen processing and presentation, and neuroactive ligand-receptor interaction, respectively.
Collapse
Affiliation(s)
- Hai-Xia Chen
- Department of Dermatology, People's Hospital of Rizhao, Rizhao
| | - Yan-Song Liu
- Department of Dermatology, Jinan Dermatosis Prevention and Control Hospital
| | - Xiu-Jie Zhang
- Department of Cardiology, The Fourth People's Hospital of Jinan, Ji-Nan, Shandong Province, China
| |
Collapse
|
5
|
Ebenezer AJ, Prasad K, Rajan S, Thangam EB. Silencing of H4R inhibits the production of IL-1β through SAPK/JNK signaling in human mast cells. J Recept Signal Transduct Res 2018; 38:204-212. [PMID: 29863427 DOI: 10.1080/10799893.2018.1468783] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
CONTEXT Mast cell (MC) activation through H4R releases various inflammatory mediators which are associated with allergic asthma. OBJECTIVES To investigate the siRNA-mediated gene silencing effect of H4R on human mast cells (HMCs) functions and the activation of stress-activated protein kinases (SAPK)/jun amino-terminal kinases (JNK) signaling pathways for the release of ineterleukin-1β (IL-1β) in HMCs. MATERIALS AND METHODS H4R expression was analyzed by RT-PCR and western blotting in human mast cell line-1 (HMC-1) cells and H4RsiRNA transfected cells. The effect of H4RsiRNA and H4R-antagonist on H4R mediated MC functions such as intracellular Ca2+ release, degranulation, IL-6 and IL-1β release, and the activation SAPK/JNK signaling pathways were studied. HMC-1 cells were stimulated with 10 μM of histamine (His) and 4-methylhistamine (4-MH) and pretreated individually with H4R-antagonist JNJ7777120 (JNJ), histamine H1 receptor (H1R)-antagonist mepyramine, and signaling molecule inhibitors SP600125 (SP) and Bay117082. RESULTS We found that the HMC-1 cells expressed H4R and H4RsiRNA treatment down regulated the H4R expression in HMC-1 cells. Both His and 4-MH induced the intracellular Ca2+ release and degranulation whereas; H4R siRNA and JNJ inhibited the effect. Furthermore, the activation of H4R caused the phosphorylation of SAPK/JNK pathways. H4R gene silencing and pretreatment with SP and JNJ decreased His and 4-MH induced phosphorylation of SAPK/JNK. We found that the activation of H4R caused the release of IL-1β (124.22 pg/ml) and IL-6 (122.50 pg/ml) on HMC-1 cells. Whereas, SAPK/JNK inhibitor (68.36 pg/ml) inhibited the H4R mediated IL-1β release. CONCLUSIONS Taken together, the silencing of H4R inhibited the H4R mediated MC functions and SAPK/JNK phosphorylation. Furthermore, the H4R activation utilized SAPK/JNK signaling pathway for IL-1β release in HMC-1 cells.
Collapse
Affiliation(s)
- Angel Jemima Ebenezer
- a Department of Biotechnology, School of Bioengineering , SRM University , Kattankulathur , India
| | - Kavya Prasad
- a Department of Biotechnology, School of Bioengineering , SRM University , Kattankulathur , India
| | - Sanjana Rajan
- a Department of Biotechnology, School of Bioengineering , SRM University , Kattankulathur , India
| | - Elden Berla Thangam
- a Department of Biotechnology, School of Bioengineering , SRM University , Kattankulathur , India
| |
Collapse
|
6
|
Thurmond RL, Venable J, Savall B, La D, Snook S, Dunford PJ, Edwards JP. Clinical Development of Histamine H 4 Receptor Antagonists. Handb Exp Pharmacol 2017; 241:301-320. [PMID: 28233185 DOI: 10.1007/164_2016_130] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The discovery of the histamine H4 receptor (H4R) provided a new avenue for the exploration of the physiological role of histamine, as well as providing a new drug target for the development of novel antihistamines. The first step in this process was the identification of selective antagonists to help unravel the pharmacology of the H4R relative to other histamine receptors. The discovery of the selective H4R antagonist JNJ 7777120 was vital for showing a role for the H4R in inflammation and pruritus. While this compound has been very successful as a tool for understanding the function of the receptor, it has drawbacks, including a short in vivo half-life and hypoadrenocorticism toxicity in rats and dogs, that prevented advancing it into clinical studies. Further research let to the discovery of JNJ 39758979, which, similar to JNJ 7777120, was a potent and selective H4R antagonist and showed anti-inflammatory and anti-pruritic activity preclinically. JNJ 39758979 advanced into human clinical studies and showed efficacy in reducing experimental pruritus and in patients with atopic dermatitis. However, development of this compound was terminated due to the occurrence of drug-induced agranulocytosis. This was overcome by developing another H4R antagonist with a different chemical structure, toreforant, that does not appear to have this side effect. Toreforant has been tested in clinical studies in patients with rheumatoid arthritis, asthma, or psoriasis. In conclusions there have been many H4R antagonists reported in the literature, but only a few have been studied in humans underscoring the difficulty in finding ligands with all of the properties necessary for testing in the clinic. Nevertheless, the clinical data to date suggests that H4R antagonists can be beneficial in treating atopic dermatitis and pruritus.
Collapse
Affiliation(s)
| | | | - Brad Savall
- Janssen Research & Development, LLC, San Diego, CA, 92121, USA
| | - David La
- Janssen Research & Development, LLC, San Diego, CA, 92121, USA
| | - Sandra Snook
- Janssen Research & Development, LLC, San Diego, CA, 92121, USA
| | - Paul J Dunford
- Janssen Research & Development, LLC, San Diego, CA, 92121, USA
| | - James P Edwards
- Janssen Research & Development, LLC, San Diego, CA, 92121, USA
| |
Collapse
|
7
|
Salem A, Almahmoudi R, Listyarifah D, Siponen M, Maaninka K, Al-Samadi A, Salo T, Eklund KK. Histamine H 4 receptor signalling in tongue cancer and its potential role in oral carcinogenesis - a short report. Cell Oncol (Dordr) 2017; 40:621-630. [PMID: 28653289 DOI: 10.1007/s13402-017-0336-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/03/2017] [Indexed: 12/25/2022] Open
Abstract
PURPOSE Recent reports indicate that histamine and its novel, high-affinity histamine H4 receptor (H4R) play a role in carcinogenesis, and thus H4R signalling has become a focus of increasing interest in the pathogenesis of many cancers. The roles of H4R in oral epithelial dysplasia (OED) and oral tongue squamous cell carcinoma (OTSCC) are unknown. The purpose of this study was to assess H4R expression in OTSCC patients and in OTSCC-derived cell lines. METHODS Biopsies taken from OED, OTSCC and healthy oral mucosa were studied by immunostaining. Primary human oral keratinocytes (HOKs) and two OTSCC-derived cell lines (HSC-3 and SCC-25) were used for the in vitro studies. Quantitative real-time PCR was used to measure oncogene expression in the stimulated HOKs. RESULTS We found that H4R-immunoreactivity was significantly reduced in the OED and OTSCC samples, especially in the samples with higher histopathological grades and noticeably increased mast cell counts. The presence of H4R in HSC-3 cells had clearly waned, in contrast to the HOKs. Gene expression data indicated that histamine-relevant inflammatory and environmental elements may participate in the regulation of oncogenes. CONCLUSIONS Our results suggest an association between H4R and oral carcinogenesis. Furthermore, our findings raise a potential implication of histamine-mediated factors in the regulation of oncogenes, possibly via mast cells, as crucial components of the tumor microenvironment. The identification of new elements that govern oral cancer development is highly relevant for the development of novel therapeutic approaches in OTSCC.
Collapse
Affiliation(s)
- Abdelhakim Salem
- Department of Clinical Medicine, Clinicum, University of Helsinki, Helsinki, Finland. .,Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Haartmaninkatu 8, Biomedicum Helsinki 1, PO Box 63, FI-00029 HUS, Helsinki, Finland.
| | - Rabeia Almahmoudi
- Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Haartmaninkatu 8, Biomedicum Helsinki 1, PO Box 63, FI-00029 HUS, Helsinki, Finland
| | - Dyah Listyarifah
- Department of Clinical Medicine, Clinicum, University of Helsinki, Helsinki, Finland.,Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Haartmaninkatu 8, Biomedicum Helsinki 1, PO Box 63, FI-00029 HUS, Helsinki, Finland.,Department of Dental Biomedical Sciences, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta, Indonesia
| | - Maria Siponen
- Department of Oral and Maxillofacial Diseases, Kuopio University Hospital, Kuopio, Finland.,Institute of Dentistry, Faculty of Health Sciences, University of Eastern Finland, Joensuu, Finland
| | | | - Ahmed Al-Samadi
- Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Haartmaninkatu 8, Biomedicum Helsinki 1, PO Box 63, FI-00029 HUS, Helsinki, Finland
| | - Tuula Salo
- Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Haartmaninkatu 8, Biomedicum Helsinki 1, PO Box 63, FI-00029 HUS, Helsinki, Finland.,Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.,Medical Research Center, Oulu University Hospital, Oulu, Finland
| | - Kari K Eklund
- Department of Clinical Medicine, Clinicum, University of Helsinki, Helsinki, Finland.,Department of Rheumatology, Helsinki University and Helsinki University Hospital, Helsinki, Finland
| |
Collapse
|
8
|
Mogilski S, Kubacka M, Łażewska D, Więcek M, Głuch-Lutwin M, Tyszka-Czochara M, Bukowska-Strakova K, Filipek B, Kieć-Kononowicz K. Aryl-1,3,5-triazine ligands of histamine H 4 receptor attenuate inflammatory and nociceptive response to carrageen, zymosan and lipopolysaccharide. Inflamm Res 2016; 66:79-95. [PMID: 27766379 PMCID: PMC5209447 DOI: 10.1007/s00011-016-0997-z] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2016] [Revised: 10/06/2016] [Accepted: 10/11/2016] [Indexed: 12/30/2022] Open
Abstract
Objective and design Histamine H4 receptor (H4R) offers a great potential for new therapeutic strategies for the treatment of inflammation-based diseases. The aim of this study is to present the pharmacological profile of two recently synthesized ligands of H4R with particular reference to their anti-inflammatory and analgesic activity. Materials and subjects We used mice and rats in the in vivo tests. We also used murine RAW 264.7 cells and isolated guinea-pig ileum in in vitro test. Treatments In the in vivo tests, animals were pre-treated with the increasing doses of investigated compounds (12.5, 25 and 50 mg/kg) and reference compounds: JNJ7777120 (25 mg/kg), indomethacin (10 mg/kg). Macrophages were pre-treated with two concentrations of tested compounds 100 and 10 µM. Methods We examined anti-inflammatory and analgesic effects of the new H4R antagonists in the in vivo models of inflammation induced by carrageenan or zymosan. We assessed the level of cAMP and release of cytokines, ROS and NO in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. Moreover, we assessed the affinity of the investigated compounds for histamine H1 receptor in functional studies. Results Both investigated compounds reduced paw edema, mechanical and thermal hyperalgesia in the carrageenan-induced acute inflammation. Moreover, administration of the investigated compounds resulted in decreased granulocyte influx and attenuated nociceptive reaction in the zymosan-induced peritonitis model. In the same model of inflammation, the investigated compounds reduced vascular permeability; however, this effect was observed only after the highest applied dose. Furthermore, the test compounds had no impact on cell viability in the experiments on RAW 264.7 macrophages. In these cells, stimulated with LPS, the test compounds decreased reactive oxygen species (ROS) production. They increased the cellular concentration of cAMP and attenuated the production of inflammatory cytokines such as TNFα and IL-1β. All results were comparable to those obtained for the reference compound JNJ7777120 with the exception of the impact on NO production. Nevertheless, this effect was similar to that obtained for the other reference compound rolipram, which is a phosphodiesterase 4 (PDE 4) inhibitor. Further experiments revealed that both of the investigated compounds possessed relatively low affinity for histamine H1 receptor and do not inhibit the activity of the PDE 4B1 enzyme. In addition, all the effects of the investigated compounds in in vivo experiments were observed at doses that did not cause neurologic deficits in rotarod test and did not reduce spontaneous locomotor activity. Conclusions Our results demonstrate the anti-inflammatory and analgesic activity of the new aryl-1,3,5-triazine derivatives, which are primarily H4R–dependent.
Collapse
Affiliation(s)
- Szczepan Mogilski
- Departament of Pharmacodynamics, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland.
| | - Monika Kubacka
- Departament of Pharmacodynamics, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland
| | - Dorota Łażewska
- Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland
| | - Małgorzata Więcek
- Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland
| | - Monika Głuch-Lutwin
- Department of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Krakow, Poland
| | - Małgorzata Tyszka-Czochara
- Department of Radioligands, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland
| | - Karolina Bukowska-Strakova
- Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.,Department of Clinical Immunology and Transplantology, Polish-American Institute of Pediatrics, Medical College, Jagiellonian University, Krakow, Poland
| | - Barbara Filipek
- Departament of Pharmacodynamics, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland
| | - Katarzyna Kieć-Kononowicz
- Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland
| |
Collapse
|
9
|
Ebenezer AJ, Arunachalam P, Elden BT. H4R activation utilizes distinct signaling pathways for the production of RANTES and IL-13 in human mast cells. J Recept Signal Transduct Res 2016; 37:133-140. [DOI: 10.1080/10799893.2016.1203938] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Angel Jemima Ebenezer
- Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur, Tamil Nadu, India
| | - Prema Arunachalam
- Department of Pediatrics, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamil Nadu, India
| | - Berla Thangam Elden
- Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur, Tamil Nadu, India
| |
Collapse
|
10
|
Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WLS, Stark H, Thurmond RL, Haas HL. International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol Rev 2016; 67:601-55. [PMID: 26084539 DOI: 10.1124/pr.114.010249] [Citation(s) in RCA: 362] [Impact Index Per Article: 45.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Histamine is a developmentally highly conserved autacoid found in most vertebrate tissues. Its physiological functions are mediated by four 7-transmembrane G protein-coupled receptors (H1R, H2R, H3R, H4R) that are all targets of pharmacological intervention. The receptors display molecular heterogeneity and constitutive activity. H1R antagonists are long known antiallergic and sedating drugs, whereas the H2R was identified in the 1970s and led to the development of H2R-antagonists that revolutionized stomach ulcer treatment. The crystal structure of ligand-bound H1R has rendered it possible to design new ligands with novel properties. The H3R is an autoreceptor and heteroreceptor providing negative feedback on histaminergic and inhibition on other neurons. A block of these actions promotes waking. The H4R occurs on immuncompetent cells and the development of anti-inflammatory drugs is anticipated.
Collapse
Affiliation(s)
- Pertti Panula
- Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry and Institute of Neurophysiology, Medical Faculty, Westfalische-Wilhelms-University, Muenster, Germany (H.L.H.); Heinrich-Heine-University Duesseldorf, Germany (H.S.); and Janssen Research & Development, LLC, San Diego, California (R.L.T.)
| | - Paul L Chazot
- Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry and Institute of Neurophysiology, Medical Faculty, Westfalische-Wilhelms-University, Muenster, Germany (H.L.H.); Heinrich-Heine-University Duesseldorf, Germany (H.S.); and Janssen Research & Development, LLC, San Diego, California (R.L.T.)
| | - Marlon Cowart
- Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry and Institute of Neurophysiology, Medical Faculty, Westfalische-Wilhelms-University, Muenster, Germany (H.L.H.); Heinrich-Heine-University Duesseldorf, Germany (H.S.); and Janssen Research & Development, LLC, San Diego, California (R.L.T.)
| | - Ralf Gutzmer
- Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry and Institute of Neurophysiology, Medical Faculty, Westfalische-Wilhelms-University, Muenster, Germany (H.L.H.); Heinrich-Heine-University Duesseldorf, Germany (H.S.); and Janssen Research & Development, LLC, San Diego, California (R.L.T.)
| | - Rob Leurs
- Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry and Institute of Neurophysiology, Medical Faculty, Westfalische-Wilhelms-University, Muenster, Germany (H.L.H.); Heinrich-Heine-University Duesseldorf, Germany (H.S.); and Janssen Research & Development, LLC, San Diego, California (R.L.T.)
| | - Wai L S Liu
- Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry and Institute of Neurophysiology, Medical Faculty, Westfalische-Wilhelms-University, Muenster, Germany (H.L.H.); Heinrich-Heine-University Duesseldorf, Germany (H.S.); and Janssen Research & Development, LLC, San Diego, California (R.L.T.)
| | - Holger Stark
- Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry and Institute of Neurophysiology, Medical Faculty, Westfalische-Wilhelms-University, Muenster, Germany (H.L.H.); Heinrich-Heine-University Duesseldorf, Germany (H.S.); and Janssen Research & Development, LLC, San Diego, California (R.L.T.)
| | - Robin L Thurmond
- Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry and Institute of Neurophysiology, Medical Faculty, Westfalische-Wilhelms-University, Muenster, Germany (H.L.H.); Heinrich-Heine-University Duesseldorf, Germany (H.S.); and Janssen Research & Development, LLC, San Diego, California (R.L.T.)
| | - Helmut L Haas
- Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry and Institute of Neurophysiology, Medical Faculty, Westfalische-Wilhelms-University, Muenster, Germany (H.L.H.); Heinrich-Heine-University Duesseldorf, Germany (H.S.); and Janssen Research & Development, LLC, San Diego, California (R.L.T.)
| |
Collapse
|
11
|
Abiuso AMB, Berensztein E, Pagotto RM, Pereyra EN, Medina V, Martinel Lamas DJ, Besio Moreno M, Pignataro OP, Mondillo C. H4 histamine receptors inhibit steroidogenesis and proliferation in Leydig cells. J Endocrinol 2014; 223:241-53. [PMID: 25253872 DOI: 10.1530/joe-14-0401] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The histamine H4 receptor (HRH4), discovered only 13 years ago, is considered a promising drug target for allergy, inflammation, autoimmune disorders and cancer, as reflected by a steadily growing number of scientific publications and patent applications. Although the presence of HRH4 has been evidenced in the testis, its specific localization or its role has not been established. Herein, we sought to identify the possible involvement of HRH4 in the regulation of Leydig cell function. We first evaluated its expression in MA-10 Leydig tumor cells and then assessed the effects of two HRH4 agonists on steroidogenesis and proliferation. We found that HRH4 is functionally expressed in MA-10 cells, and that its activation leads to the inhibition of LH/human chorionic gonadotropin-induced cAMP production and StAR protein expression. Furthermore, we observed decreased cell proliferation after a 24-h HRH4 agonist treatment. We then detected for the sites of HRH4 expression in the normal rat testis, and detected HRH4 immunostaining in the Leydig cells of rats aged 7-240 days, while 21-day-old rats also presented HRH4 expression in male gametes. Finally, we evaluated the effect of HRH4 activation on the proliferation of normal progenitor and immature rat Leydig cell culture, and both proved to be susceptible to the anti-proliferative effect of HRH4 agonists. Given the importance of histamine (2-(1H-imidazol-4-yl)ethanamine) in human (patho)physiology, continued efforts are directed at elucidating the emerging properties of HRH4 and its ligands. This study reveals new sites of HRH4 expression, and should be considered in the design of selective HRH4 agonists for therapeutic purposes.
Collapse
MESH Headings
- Animals
- Blotting, Western
- Bucladesine/pharmacology
- Cell Line, Tumor
- Cell Proliferation
- Cells, Cultured
- Chorionic Gonadotropin/pharmacology
- Cyclic AMP/metabolism
- Dose-Response Relationship, Drug
- Guanidines/pharmacology
- Histamine Agonists/pharmacology
- Immunohistochemistry
- Indoles/pharmacology
- Leydig Cells/drug effects
- Leydig Cells/metabolism
- Male
- Microscopy, Confocal
- Oximes/pharmacology
- Phosphoproteins/metabolism
- Progesterone/metabolism
- Rats, Sprague-Dawley
- Receptors, G-Protein-Coupled/agonists
- Receptors, G-Protein-Coupled/metabolism
- Receptors, Histamine/metabolism
- Receptors, Histamine H4
- Testis/metabolism
- Thiourea/analogs & derivatives
- Thiourea/pharmacology
Collapse
Affiliation(s)
- Adriana María Belén Abiuso
- Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina
| | - Esperanza Berensztein
- Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina
| | - Romina María Pagotto
- Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina
| | - Elba Nora Pereyra
- Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina
| | - Vanina Medina
- Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina
| | - Diego José Martinel Lamas
- Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina
| | - Marcos Besio Moreno
- Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina
| | - Omar Pedro Pignataro
- Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina
| | - Carolina Mondillo
- Laboratory of Molecular Endocrinology and Signal TransductionInstitute of Biology and Experimental Medicine, National Scientific and Technical Research Council (IByME-CONICET), CP 1428 Buenos Aires, ArgentinaResearch LaboratoryEndocrinology Service, Garrahan Pediatric Hospital, CP 1245 Buenos Aires, ArgentinaCell Biology UnitInstitut Pasteur de Montevideo, CP 11400 Montevideo, UruguayLaboratory of RadioisotopesSchool of Pharmacy and Biochemistry, University of Buenos Aires, CP 1113 Buenos Aires, ArgentinaInstitute for Biomedical Research (BIOMED)School of Medical Sciences, Pontifical Catholic University of Argentina, National Scientific and Technical Research Council (UCA-CONICET), CP1107 Buenos Aires, ArgentinaDepartment of Biological ChemistrySchool of Sciences, University of Buenos Aires, CP 1428 Buenos Aires, Argentina
| |
Collapse
|
12
|
Salem A, Al-Samadi A, Stegajev V, Stark H, Häyrinen-Immonen R, Ainola M, Hietanen J, Konttinen YT. Histamine H4 receptor in oral lichen planus. Oral Dis 2014; 21:378-85. [PMID: 25207698 DOI: 10.1111/odi.12290] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2014] [Revised: 09/03/2014] [Accepted: 09/03/2014] [Indexed: 01/21/2023]
Abstract
OBJECTIVES Oral lichen planus (OLP) is an autoimmune disease characterized by a band-like T-cell infiltrate below the apoptotic epithelial cells and degenerated basement membrane. We tested the hypothesis that the high-affinity histamine H4 receptors (H4 Rs) are downregulated in OLP by high histamine concentrations and proinflammatory T-cell cytokines. MATERIALS AND METHODS Immunohistochemistry and immunofluorescence staining, image analysis and quantitative real-time polymerase chain reaction of tissue samples and cytokine-stimulated cultured SCC-25 and primary human oral keratinocytes. RESULTS H4 R immunoreactivity was weak in OLP and characterized by mast cell (MC) hyperplasia and degranulation. In contrast to controls, H4 R immunostaining and MC counts were negatively correlated in OLP (P = 0.003). H4 R agonist at nanomolar levels led to a rapid internalization of H4 Rs, whereas high histamine concentration and interferon-γ decreased HRH4 -gene transcripts. CONCLUSION Healthy oral epithelial cells are equipped with H4 R, which displays a uniform staining pattern in a MC-independent fashion. In contrast, in OLP, increased numbers of activated MCs associate with increasing loss of epithelial H4 R. Cell culture experiments suggest a rapid H4 R stimulation-dependent receptor internalization and a slow cytokine-driven decrease in H4 R synthesis. H4 R may be involved in the maintenance of healthy oral mucosa. In OLP, this maintenance might be impaired by MC degranulation and inflammatory cytokines.
Collapse
Affiliation(s)
- A Salem
- Department of Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; Department of Oral Pathology, University of Helsinki, Helsinki, Finland
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Pagotto RM, Pereyra EN, Monzón C, Mondillo C, Pignataro OP. Histamine inhibits adrenocortical cell proliferation but does not affect steroidogenesis. J Endocrinol 2014; 221:15-28. [PMID: 24424290 DOI: 10.1530/joe-13-0433] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Histamine (HA) is a neurotransmitter synthesized in most mammalian tissues exclusively by histidine decarboxylase enzyme. Among the plethora of actions mediated by HA, the modulatory effects on steroidogenesis and proliferation in Leydig cells (LCs) have been described recently. To determine whether the effects on LCs reported could be extrapolated to all steroidogenic systems, in this study, we assessed the effect of this amine on adrenal proliferation and steroidogenesis, using two adrenocortical cell lines as experimental models, murine Y1 cells and human NCI-H295R cells. Even when steroidogenesis was not modified by HA in adrenocortical cells, the biogenic amine inhibited the proliferation of H295R cells. This action was mediated by the activation of HRH1 subtype and an increase in the production of inositol phosphates as second messengers, causing cell-cycle arrest in the G2/M phase. These results indicate a new role for HA in the proliferation of human adrenocortical cells that could contribute to a better understanding of tumor pathology as well as to the development of new therapeutic agents.
Collapse
Affiliation(s)
- Romina Maria Pagotto
- Laboratory of Molecular Endocrinology and Signal Transduction, Institute of Biology and Experimental Medicine, National Research Council (IByME-CONICET), Vuelta de Obligado 2490, CP 1428 Buenos Aires, Argentina Department of Biological Chemistry, School of Sciences, University of Buenos Aires (UBA), CP 1428 Buenos Aires, Argentina
| | | | | | | | | |
Collapse
|
14
|
Cai WK, Hu J, Li T, Meng JR, Ma X, Yin SJ, Zhao CH, He GH, Xu GL. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer. Eur J Cancer 2014; 50:1195-206. [PMID: 24447834 DOI: 10.1016/j.ejca.2013.12.025] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2013] [Revised: 10/30/2013] [Accepted: 12/27/2013] [Indexed: 12/12/2022]
Abstract
Previous investigations found that epithelial-to-mesenchymal transition (EMT) was an important character of non-small cell lung cancer (NSCLC) and it was also suggested that histamine H4 receptors may have a role in preventing EMT progress in certain kind of tumours. However, the effect of H4 receptor activation on EMT progress of NSCLC and its potential mechanisms remain unclear. Therefore, we performed both in vitro and in vivo experiments to explore the effects of specific H4 receptor agonist 4-methylhistamine and antagonist JNJ7777120 on EMT progress. We showed the expression of H4 receptors in NSCLC and found that 4-methylhistamine increased the expression of the epithelial marker E-cadherin and decreased the expression of Vimentin, the mesenchymal marker, in both NSCLC cell lines and xenograft NSCLC tumours. Pretreatment with JNJ7777120 or H4 receptor gene silencing decreased while overexpression of H4 receptors facilitated this effect of 4-methylhistamine. Furthermore, we showed that down-regulation of cyclic adenosine monophosphate (cAMP) was the secondary signalling after H4 receptor activation, which in turn resulted in inactivation of transforming growth factor-β1 (TGF-β1) pathway and down-regulation of several important EMT inducing factors such as ZEB1, Snail and Slug. In conclusion, these findings revealed the anti-EMT effect of histamine H4 receptor activation in NSCLC, which provide novel insight into the development mechanism of NSCLC; and H4 receptors may be a new therapeutic target for NSCLC treatment.
Collapse
Affiliation(s)
- Wen-Ke Cai
- Department of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming, China; Department of Cardio-Thoracic Surgery, Kunming General Hospital of Chengdu Military Region, Kunming, China
| | - Jing Hu
- Experiment Teaching Center of Basic Medicine, The Fourth Military Medical University, Xi'an, China; Department of Histology and Embryology, The Fourth Military Medical University, Xi'an, China
| | - Teng Li
- Department of Histology and Embryology, The Fourth Military Medical University, Xi'an, China
| | - Jing-Ru Meng
- Department of Pharmacology, The Fourth Military Medical University, Xi'an, China
| | - Xue Ma
- Department of Pharmacology, The Fourth Military Medical University, Xi'an, China
| | - Sun-Jun Yin
- Department of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming, China
| | - Can-Hu Zhao
- Department of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming, China
| | - Gong-Hao He
- Department of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming, China.
| | - Gui-Li Xu
- Department of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming, China.
| |
Collapse
|
15
|
Massari NA, Medina VA, Cricco GP, Martinel Lamas DJ, Sambuco L, Pagotto R, Ventura C, Ciraolo PJ, Pignataro O, Bergoc RM, Rivera ES. Antitumor activity of histamine and clozapine in a mouse experimental model of human melanoma. J Dermatol Sci 2013; 72:252-62. [PMID: 23999004 DOI: 10.1016/j.jdermsci.2013.07.012] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2013] [Revised: 07/16/2013] [Accepted: 07/22/2013] [Indexed: 12/09/2022]
Abstract
BACKGROUND Functional presence of histamine H4 receptor (H4R) was demonstrated in human melanoma cell lines and biopsies. OBJECTIVE The purposes of this work were to investigate signal transduction pathways and biological responses triggered by the activation of H4R in human primary (WM35) and metastatic (M1/15) melanoma cell lines and to evaluate the in vivo antitumor activity of histamine (HA) and clozapine (CLZ) on human M1/15 melanoma xenografts. METHODS Clonogenic assay, incorporation of BrdU, cell cycle distribution, phosphorylation levels of ERK1/2 and cAMP production were evaluated in vitro. An experimental human melanoma model was developed into athymic nude mice. Tumor growth, survival and histochemical studies were performed in order to investigate the expression levels of H4R, HA, PCNA, mitotic index (MI), and angiogenesis. RESULTS The results indicate that H4R agonists inhibited forskolin-induced cAMP levels only in M1/15 cells while increased phosphorylation levels of ERK1/2 and decreased proliferation in both cell types. In vivo studies show that HA and CLZ (1mgkg(-1), sc) significantly increased median survival and decreased tumor volume. These effects were associated to a reduction in MI, in the expression of proliferation marker and in intratumoral neovascularization. CONCLUSIONS We conclude that HA and CLZ exhibit an antitumoral effect in vitro and in vivo on human melanoma, suggesting the therapeutic potential of these compounds for the treatment of malignant melanoma.
Collapse
Affiliation(s)
- Noelia A Massari
- Laboratory of Radioisotopes, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires 1113, Argentina
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Seifert R, Strasser A, Schneider EH, Neumann D, Dove S, Buschauer A. Molecular and cellular analysis of human histamine receptor subtypes. Trends Pharmacol Sci 2013; 34:33-58. [PMID: 23254267 PMCID: PMC3869951 DOI: 10.1016/j.tips.2012.11.001] [Citation(s) in RCA: 126] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2012] [Revised: 11/03/2012] [Accepted: 11/05/2012] [Indexed: 01/08/2023]
Abstract
The human histamine receptors hH(1)R and hH(2)R constitute important drug targets, and hH(3)R and hH(4)R have substantial potential in this area. Considering the species-specificity of pharmacology of H(x)R orthologs, it is important to analyze hH(x)Rs. Here, we summarize current knowledge of hH(x)Rs endogenously expressed in human cells and hH(x)Rs recombinantly expressed in mammalian and insect cells. We present the advantages and disadvantages of the various systems. We also discuss problems associated with the use of hH(x)R antibodies, an issue of general relevance for G-protein-coupled receptors (GPCRs). There is much greater overlap in activity of 'selective' ligands for other hH(x)Rs than the cognate receptor subtype than generally appreciated. Studies with native and recombinant systems support the concept of ligand-specific receptor conformations, encompassing agonists and antagonists. It is emerging that for characterization of hH(x)R ligands, one cannot rely on a single test system and a single parameter. Rather, multiple systems and parameters have to be studied. Although such studies are time-consuming and expensive, ultimately, they will increase drug safety and efficacy.
Collapse
Affiliation(s)
- Roland Seifert
- Institute of Pharmacology, Medical School of Hannover, Hannover, Germany.
| | | | | | | | | | | |
Collapse
|
17
|
Kastner S, Voss T, Keuerleber S, Glöckel C, Freissmuth M, Sommergruber W. Expression of G protein-coupled receptor 19 in human lung cancer cells is triggered by entry into S-phase and supports G(2)-M cell-cycle progression. Mol Cancer Res 2012; 10:1343-58. [PMID: 22912338 DOI: 10.1158/1541-7786.mcr-12-0139] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
It has long been known that G protein-coupled receptors (GPCR) are subject to illegitimate expression in tumor cells. Presumably, hijacking the normal physiologic functions of GPCRs contributes to all biologic capabilities acquired during tumorigenesis. Here, we searched for GPCRs that were expressed in lung cancer: the mRNA encoding orphan G protein-coupled receptor 19 (GPR19) was found frequently overexpressed in tissue samples obtained from patients with small cell lung cancer. Several observations indicate that overexpression of Gpr19 confers a specific advantage to lung cancer cells by accelerating transition through the cell-cycle. (i) Knockdown of Gpr19 mRNA by RNA interference reduced cell growth of human lung cancer cell lines. (ii) Cell-cycle progression through G(2)-M-phase was impaired in cells transfected with siRNAs directed against Gpr19 and this was associated with increased protein levels of cyclin B1 and phosphorylated histone H3. (iii) The expression levels of Gpr19 mRNA varied along the cell-cycle with a peak observed in S-phase. (iv) The putative control of Gpr19 expression by E2F transcription factors was verified by chromatin immunoprecipitation: antibodies directed against E2F-1 to -4 allowed for the recovery of the Gpr19 promoter. (v) Removal of E2F binding sites in the Gpr19 promoter diminished the expression of a luciferase reporter. (vi) E2f and Gpr19 expression correlated in lung cancer patient samples. To the best of knowledge, this is the first example of a GPCR showing cell-cycle-specific mRNA expression. Our data also validate GPR19 as a candidate target when overexpressed in lung cancer.
Collapse
Affiliation(s)
- Stefan Kastner
- Boehringer Ingelheim RCV GmbH & Co KG, Department of Lead Discovery, Dr. Boehringer-Gasse 5-11, 1121 Vienna, Austria
| | | | | | | | | | | |
Collapse
|
18
|
Passani MB, Ballerini C. Histamine and neuroinflammation: insights from murine experimental autoimmune encephalomyelitis. Front Syst Neurosci 2012; 6:32. [PMID: 22563309 PMCID: PMC3342557 DOI: 10.3389/fnsys.2012.00032] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2012] [Accepted: 04/14/2012] [Indexed: 11/13/2022] Open
Abstract
Multiple sclerosis (MS) is a chronic inflammatory, neurodegenerative disease of the CNS whose pathogenesis remains largely unknown, and available therapies are rarely successful in reversing neurological deficits or stopping disease progression. Ongoing studies on MS and the widely used murine model of experimental autoimmune encephalomyelitis (EAE) are focused on the many components of this complex and heterogeneous neurodegenerative disease in the hope of providing a mechanism-based characterization of MS that will afford successful strategies to limit and repair the neuronal damage. Recently, histamine has been postulated to have a key regulatory role in EAE and MS pathogenesis. Histamine is a mediator of inflammation and immune responses, exerting its many actions through four G protein-coupled receptors (H1,2,3,4R) that signal through distinct intracellular pathways and have different therapeutic potentials as they vary in expression, isoform distribution, signaling properties, and function. Immune cells involved in MS/EAE, including dendritic cells (DCs) and T lymphocytes, express H1R, H2R and H4R, and histamine may have varying and counteracting effects on a particular cell type, depending on the receptor subtypes being activated. Here, we review evidence of the complex and controversial role of histamine in the pathogenesis of MS and EAE and evaluate the therapeutic potential of histaminergic ligands in the treatment of autoimmune diseases.
Collapse
Affiliation(s)
- Maria B Passani
- Dipartimento di Farmacologia Preclinica e Clinica, Universita' di Firenze Firenze, Italy
| | | |
Collapse
|
19
|
Humbert-Claude M, Davenas E, Gbahou F, Vincent L, Arrang JM. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl) 2012; 220:225-41. [PMID: 21912901 DOI: 10.1007/s00213-011-2471-5] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2011] [Accepted: 08/24/2011] [Indexed: 12/11/2022]
Abstract
RATIONALE The basis of the unique clinical profile of the antipsychotic clozapine is not yet elucidated. Brain histamine receptors may play a role in schizophrenia and its treatment, but their involvement in the profile of clozapine remained unknown. OBJECTIVES We explored the properties of clozapine and its two metabolites, N-desmethylclozapine (NDMC) and clozapine N-oxide, at the four human histaminergic receptors. We compared their active concentrations with their blood concentrations in patients treated by clozapine. We investigated the changes in receptor densities induced in rat brain by repeated administration of a therapeutic dose of clozapine. RESULTS Clozapine and NDMC behaved as very potent, and partial, H(1)-receptor inverse agonists, weak, and full, H(2)-receptor inverse agonists, moderate, and protean, H(3)-receptor agonists, and moderate, and partial, H(4)-receptor agonists. Taking into account their micromolar mean blood concentrations found in 75 treated patients, and assuming that they are enriched in human brain as they are in rat brain, a full occupation of H(1)-, H(3)-, and H(4)-receptors, and a partial occupation of H(2) receptors, is expected. In agreement, repeated administration of clozapine at a therapeutic dose (20 mg/kg/day for 20 days) induced an up-regulation of H(1)- and H(2)-receptors in rat brain. CONCLUSIONS Clozapine and its active metabolite NDMC interact with the four human histamine receptors at clinically relevant concentrations. This interaction may substantiate, at least in part, the atypical antipsychotic profile of clozapine, as well as its central and peripheral side effects such as sedation and weight gain.
Collapse
Affiliation(s)
- Marie Humbert-Claude
- Laboratoire de Neurobiologie et Pharmacologie Moléculaire, Centre de Psychiatrie et Neurosciences (CPN, U 894), INSERM, 2 ter rue d'Alésia, 75014 Paris, France
| | | | | | | | | |
Collapse
|
20
|
Zhang C, Xiong Y, Li J, Yang Y, Liu L, Wang W, Wang L, Li M, Fang Z. Deletion and down-regulation of HRH4 gene in gastric carcinomas: a potential correlation with tumor progression. PLoS One 2012; 7:e31207. [PMID: 22363581 PMCID: PMC3282702 DOI: 10.1371/journal.pone.0031207] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2011] [Accepted: 01/04/2012] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Histamine is an established growth factor for gastrointestinal malignancies. The effect of histamine is largely determined locally by the histamine receptor expression pattern. Histamine receptor H4 (HRH4), the newest member of the histamine receptor family, is positively expressed on the epithelium of the gastrointestinal tract, and its function remains to be elucidated. Previously, we reported the decreased expression of HRH4 in colorectal cancers and revealed its correlation with tumor proliferation. In the current study, we aimed to investigate the abnormalities of HRH4 gene in gastric carcinomas (GCs). METHODOLOGY/PRINCIPAL FINDINGS We analyzed H4R expression in collected GC samples by quantitative PCR, Western blot analysis, and immunostaining. Our results showed that the protein and mRNA levels of HRH4 were reduced in some GC samples, especially in advanced GC samples. Copy number decrease of HRH4 gene was observed (17.6%, 23 out of 131), which was closely correlated with the attenuated expression of H4R. In vitro studies, using gastric cancer cell lines, showed that the alteration of HRH4 expression on gastric cancer cells influences tumor growth upon exposure to histamine. CONCLUSIONS/SIGNIFICANCE We show for the first time that deletion of HRH4 gene is present in GC cases and is closely correlated with attenuated gene expression. Down-regulation of HRH4 in gastric carcinomas plays a role in histamine-mediated growth control of GC cells.
Collapse
Affiliation(s)
- Chao Zhang
- Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Guangdong Province, Shenzhen, People's Republic of China
| | - Yi Xiong
- Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Guangdong Province, Shenzhen, People's Republic of China
| | - Jiana Li
- Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Guangdong Province, Shenzhen, People's Republic of China
| | - Yang Yang
- Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Guangdong Province, Shenzhen, People's Republic of China
| | - Li Liu
- Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Guangdong Province, Shenzhen, People's Republic of China
| | - Wen Wang
- Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Guangdong Province, Shenzhen, People's Republic of China
| | - Luo Wang
- Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Guangdong Province, Shenzhen, People's Republic of China
| | - Manhui Li
- Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Guangdong Province, Shenzhen, People's Republic of China
| | - Zhengyu Fang
- Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Guangdong Province, Shenzhen, People's Republic of China
- * E-mail:
| |
Collapse
|
21
|
Fang Z, Yao W, Xiong Y, Li J, Liu L, Shi L, Zhang W, Zhang C, Nie L, Wan J. Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression. BMC Cancer 2011; 11:195:1-11. [PMID: 21609450 PMCID: PMC3128004 DOI: 10.1186/1471-2407-11-195] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2011] [Accepted: 05/24/2011] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND Earlier studies have reported the production of histamine in colorectal cancers (CRCs). The effect of histamine is largely determined locally by the histamine receptor expression pattern. Recent evidence suggests that the expression level of histamine receptor H4 (HRH4) is abnormal in colorectal cancer tissues. However, the role of HRH4 in CRC progression and its clinical relevance is not well understood. The aim of this study is to evaluate the clinical and molecular phenotypes of colorectal tumors with abnormal HRH4 expression. METHODS Immunoblotting, real-time PCR, immunofluorescence and immunohistochemistry assays were adopted to examine HRH4 expression in case-matched CRC samples (n = 107) and adjacent normal tissues (ANTs). To assess the functions of HRH4 in CRC cells, we established stable HRH4-transfected colorectal cells and examined cell proliferation, colony formation, cell cycle and apoptosis in these cells. RESULTS The protein levels of HRH4 were reduced in most of the human CRC samples regardless of grade or Dukes classification. mRNA levels of HRH4 were also reduced in both early-stage and advanced CRC samples. In vitro studies showed that HRH4 over-expression caused growth arrest and induced expression of cell cycle proteins in CRC cells upon exposure to histamine through a cAMP -dependent pathway. Furthermore, HRH4 stimulation promoted the 5-Fu-induced cell apoptosis in HRH4-positive colorectal cells. CONCLUSION The results from the current study supported previous findings of HRH4 abnormalities in CRCs. Expression levels of HRH4 could influence the histamine-mediated growth regulation in CRC cells. These findings suggested a potential role of abnormal HRH4 expression in the progression of CRCs and provided some new clues for the application of HRH4-specific agonist or antagonist in the molecular therapy of CRCs.
Collapse
Affiliation(s)
- Zhengyu Fang
- Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Guangdong Province, Shenzhen, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
|
23
|
Yu F, Bonaventure P, Thurmond RL. The Future Antihistamines: Histamine H3 and H4 Receptor Ligands. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2010; 709:125-40. [DOI: 10.1007/978-1-4419-8056-4_12] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|